Osteoarthritis (OA) is a common and prevalent degenerative joint disease characterized by degradation of the articular cartilage. However, none of disease-modifying OA drugs is approved currently. Teriparatide (PTH (1–34)) might stimulate chondrocyte proliferation and cartilage regeneration via some uncertain mechanisms. Relevant therapies of PTH (1–34) on OA with such effects have recently gained increasing interest, but have not become widespread practice. Thus, we launch this systematic review (SR) to update the latest evidence accordingly. A comprehensive literature search was conducted in PubMed, Web of Science, MEDLINE, the Cochrane Library, and Embase from their inception to February 2022. Studies investigating the effects of the PTH (1–34) on OA were obtained. The quality assessment and descriptive summary were made of all included studies. Overall, 307 records were identified, and 33 studies were included. In vivo studies (n = 22) concluded that PTH (1–34) slowed progression of OA by alleviating cartilage degeneration and aberrant remodeling of subchondral bone (SCB). Moreover, PTH (1–34) exhibited repair of cartilage and SCB, analgesic, and anti-inflammatory effects. In vitro studies (n = 11) concluded that PTH (1–34) was important for chondrocytes via increasing the proliferation and matrix synthesis but preventing apoptosis or hypertrophy. All included studies were assessed with low or unclear risk of bias in methodological quality. The SR demonstrated that PTH (1–34) could alleviate the progression of OA. Moreover, PTH (1–34) had beneficial effects on osteoporotic OA (OPOA) models, which might be a therapeutic option for OA and OPOA treatment.
Guoqing Li, Su Liu, and Huihui Xu contributed equally to this work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PTH (1–34)
Teriparatide
OA
Osteoarthritis
SR
Systematic review
SCB
Subchondral bone
ECM
Extracellular matrix
COL II
Type II collagen
AGC
Aggrecan
TNF-α
Tumor necrosis factor-α
IL-1β
Interleukin-1β
DMOADs
Disease-modifying OA drugs
OP
Osteoporosis
PRISMA
Preferred Reporting Items for Systematic Review and Meta-Analysis
PROSPERO
Prospective Register of Systematic Reviews
MeSH
Medical Subject Headings
CRIS
Checklist for Reporting In-vitro Studies
CIOA
Collagenase-induced osteoarthritis
OPOA
Osteoporotic osteoarthritis
OVX
Ovariectomized
ACLT
Anterior cruciate ligament transection
MLI
Meniscal ligamentous injury
MCC
Mandibular condylar cartilage
DMM
Destabilization of the medial meniscus
SD
Sprague–Dawley
nM
Nmol/L
PIOA
Papain-induced osteoarthritis
MSCs
Mesenchymal stem cells
M
mol/L
RA
Rheumatoid arthritis
PTHrP
Parathyroid hormone-related protein
COLX
Type X collagen
MMP13
Matrix metallopeptidase 13
ADAMTS4
ADAM Metallopeptidase With Thrombospondin Type 1 Motif 4
PTH1R
Parathyroid 1 receptor
OPG
Osteoprotegerin
RANKL
Receptor activator of NF-κB ligand
COX2
Cyclooxygenase-2
iNOS
Inducible nitric oxide synthase
MAPK
Mitogen-activated protein kinase
mTOR
Target of rapamycin
THA
Total hip arthroplasty
TKA
Total knee arthroplasty
SC
Subcutaneous injection
IA
Intra-articular
PFJOA
Patellofemoral joint osteoarthritis
pM
pmol/L
μM
μmol/L
Background
Osteoarthritis (OA) is a common musculoskeletal disorder and prevalent degenerative disease worldwide [1, 2]. Both non-load bearing and load-bearing joints are affected by multiple factors such as trauma, senility, gender, genetics, and obesity [3], which resulted in functional disability or decreased quality of life. Articular cartilage is an avascular tissue, while chondrocytes are unique cellular components and responsible for the maintenance of the extracellular matrix (ECM) via the balance of catabolism and anabolism. Type II collagen (COL II) and aggrecan (AGC) are secreted proteins, which are essential for the integrity of cartilage. Break-down of chondrocytes is one of the molecular characteristics of OA, which is characterized by progressive damage including cartilage erosion, synovitis, and subchondral bone (SCB) disturbance. The normal metabolism of cartilage is disturbed by inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), shifting to catabolism and ECM degradation [4]. Oxidative stress and apoptosis generate the decrease of chondrocytes and loss of cartilage [5]. The schematic diagram of normal and osteoarthritic joint was illustrated in Fig. 1.
Fig. 1
The schematic structures of normal (left part) and osteoarthritic (right part) joint. Multiple factors and pro-inflammatory cytokines resulting chondrocytes catabolism and ECM degradation in OA joints
×
Recommendation of OA treatment includes physiotherapy, pharmacological, and surgical interventions [6, 7]. Physiotherapy should be advocated due to its safety and effectiveness. However, limited choices and less effectiveness of drugs were restricted to symptom relief and accompanied by adverse effects [8]. Currently, no disease-modifying OA drugs (DMOADs) are available to alleviate the progression of OA. And therefore, strategies to protect the chondrocytes and the cartilage represent potential new therapeutic modalities.
Anzeige
Teriparatide (PTH (1–34)) contains 34 amino acids of parathyroid hormone, which was applied on the treatment of osteoporosis (OP) and bone fracture [9, 10] by maintaining calcium homeostasis, increasing cortical and trabecular thickness, and stimulating bone formation [11]. In addition, quantitative studies documented PTH (1–34) could mediate anabolic effects among chondrocytes [12] by enhancing chondral regeneration [13] and increasing ECM synthesis [14]. Experimental studies investigated the benefits of PTH (1–34) on OA pitiful without frequent practice or systematic review (SR). For these reasons, we reviewed the accessible research to update the effect of PTH (1–34) on OA.
Methods
Protocol
We performed this SR in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statements [15]. We recorded the study protocol on the international Prospective Register of Systematic Reviews (PROSPERO) with code CRD42022315089.
Literature search strategy
A comprehensive literature search was conducted in 5 databases (PubMed, Web of Science, Medline, the Cochrane Library, and Embase) from their inception to February 2022. The Medical Subject Headings (MeSH) terms and keywords were combined with boolean operators, “OR” or “AND”. The MeSH terms and keywords were as follows: “Teriparatide,” “hPTH (1–34),” “Human Parathyroid Hormone (1–34),” “Parathar,” “Teriparatide Acetate,” “Forteo,” “Osteoarthritis,” “Osteoarthritides,” “Osteoarthrosis,” “Osteoarthroses,” “Arthritis,” “Degenerative,” “Arthritides,” “Degenerative,” “Degenerative Arthritides,” “Degenerative Arthritis,” “Arthrosis,” “Arthroses,” “Osteoarthrosis Deformans.” In addition, the reference lists of all retrieved papers were further obtained manually. The search strategy of these five databases is provided in Additional file 1.
Inclusion and exclusion criteria
The eligible studies should meet the following criteria: (1) prospective and retrospective studies, randomized and controlled clinical trials; (2) patients or animal models with OA treated by PTH (1–34) directly or indirectly; and (3) studies published in the English language. Studies were excluded from this review if they were reviews, research protocols, abstracts only, commentaries, or editorials.
Study selection
All records of five databases were imported into the reference management software program Endnote X 9.3.3. After the removal of duplicates, two authors (GQL and SL) independently reviewed the titles and abstracts of the remaining records for relevance to the topic. Studies that potentially or completely met the inclusion criteria were kept and full texts were retrieved. The two authors (GQL and SL) independently assessed the full texts to decide whether to keep the records or not. A consensus meeting with a third reviewer (FY) was used to resolve discrepancies. The final included studies were reviewed by all authors for agreement.
Data extraction
The information of in vivo and in vitro studies was extracted in the standardized information forms: (1) first author’s surname, year of publication, and country; (2) subjects; (3) intervention; (4) dose and duration of treatment; (5) route; and (6) findings. Two investigators (GQL and SL) independently reviewed and extracted information from included studies. Disagreements were discussed with a third author (JW) to reach a consensus.
Quality assessment
The methodological quality of the in vivo studies was assessed by SYRCLE’s risk of bias tool [16] while the in vitro studies with Checklist for Reporting In-vitro Studies (CRIS) instruction [17]. Two authors (GQL and SL) independently assessed the methodological quality of the articles included, and discrepancies were resolved by discussion with a third author (FY).
Results
Identification of relevant studies
The initial literature search resulted in 296 articles from PubMed (n = 35), Web of Science (n = 26), MEDLINE (n = 90), the Cochrane Library (n = 101), and Embase (n = 44) (Fig. 2). There are 152 duplicate records that were removed, and the remaining 144 records were screened by title and 103 records were excluded. Next, 41 full-text articles were assessed for their eligibility. Nineteen were excluded for (1) review (n = 5); (2) research protocol (n = 3); (3) abstract only (n = 2); (4) commentaries or editorials (n = 4); and (5) subjects treated without PTH (1–34) (n = 5). In addition, 11 additional records were added. Finally, 33 papers were considered and included.
Fig. 2
PRISMA flowchart (Preferred Reporting Items for Systematic Reviews). A comprehensive literature search was conducted and from their inception to February, 2022 and of 33 studies were included ultimately
×
Anzeige
In vivo studies showed potential effects of PTH (1–34) on OA models
According to the inclusion criteria, 22 in vivo studies were included (Table 1). The studies were conducted in numerous countries including China (Shao et al., 2020 [18]; Shao et al., 2021 [19]; Chen et al. 2021 [20]; Chen et al. 2018 [21]; Rajalakshmanan et al. 2012 [22]; Ma et al. 2017 [23]; Zhang et al. 2022 [24]; Chang et al. 2009 [25]; Yan et al. 2014 [26]; Dai et al. 2016 [27]; Cui et al. 2019 [28]; He et al. 2021 [29]; Longo et al. 2020 [30]), Germany (Orth et al. 2014 [31]; Orth et al. 2013 [32]), and the USA (Dutra et al. 2017 [33]; Sampson et al. 2011 [34]; Brien et al. 2017 [35]; Bagi et al. 2015 [36]; Antunes et al. 2013 [37]), Spain (Lugo et al. 2012 [38]; Bellido et al. 2011 [39]).
Table 1
Characteristics of in vivo studies about the effect of teriparatide on OA
PTH (1–34) alleviates OA progression after ACLT and histological molecular changes by reducing chondrocyte terminal differentiation and apoptosis and by increasing autophagy
PTH (1–34) reduces the accumulation of senescent cells in SCB by inhibiting p16 and improves bone marrow microenvironment to active bone remodeling process, indicating a potential preventative and therapeutic treatment for age-related OA
PTH (1–34) promotes the regenerative and chondroprotective effects of the tissue-engineered meniscus total implantation in a canine model by inhibiting the terminal differentiation of BMSC chondrogenesis and degeneration of knee joint cartilage
PTH (1–34) increases the number of Col1a1/Col2a1/Col10a1-positive cells; bone volume fraction, tissue density and trabecular thickness of the SCB; proteoglycan distribution with a concomitant increase in MCC mineralization; chondrocytes differentiation and increases mineralization
A single drug will have the capacity to reduce joint inflammation, curb excessive bone remodeling, improve cartilage regeneration, and reduce pain
Both Zol and PTH does not prevent or correct the deterioration of the hyaline cartilage, thickening of the SCB plate, osteophyte formation, and mechanical incapacity of the OA
Studies implied that PTH (1–34) exhibited protective effects on both cartilage and SCB. Shao et al. concluded similar findings among collagenase-induced OA (CIOA) mouse models in a dose-dependent manner via the JAK2/STAT3 and WNT5A/ROR2 signaling pathway [18, 40]. At the dose of 10 μg/kg/day of PTH (1–34), Orth et al. reported that PTH (1–34) could broaden the calcified cartilage layer, result in cartilage degeneration, and induce alterations in the microarchitecture of SCB to provoke early OA [31]. Moreover, PTH (1–34) would stimulate articular cartilage and SCB repair [41]. Bellido et al. suggested that PTH (1–34) could improve microstructural and remodeling parameters of SCB, which contributed to preventing cartilage damage and OA progression in OVX and ACLT rabbits [39].
PTH (1–34) would reduce the predisposing factors for OA progression. At the dose of 40 μg/kg/day, Cui et al. believed that PTH (1–34) reduced the accumulation of senescent cells in SCB by inhibiting p16 for age-related OA [28]. In addition, Sampson et al. considered that it might be useful to decelerate cartilage degeneration among meniscal ligamentous injury (MLI) mice and induce ECM regeneration among OA patients [34]. Bagi et al. concluded that PTH (1–34) would reduce joint inflammation, curb excessive bone remodeling, improve cartilage regeneration, and reduce pain in post-traumatic OA rats [36]. At the dose of 80 μg/kg/day of PTH (1–34), Dutra et al. found that it could result in mineralization and alteration of the mandibular condylar cartilage (MCC), with cartilage degeneration and abnormal remodeling of the SCB [33]. He et al. concluded that PTH (1–34) had an obvious analgesic and anti-inflammatory effect on DMM mice via the PKA and the NF-κB signaling pathways [29]. Brien et al. concluded that it would increase the differentiation and mineralization of chondrocytes as well as density of the SCB among the transgenic mice [35].
PTH (1–34) prevents cartilage damage and retards the deterioration of SCB. Yan et al. concluded that 15 μg/kg/day of PTH (1–34) protected the cartilage among guinea pigs [26]. Dai et al. found that 24 μg/kg/day of PTH (1–34) exhibited protective effects on cartilage degeneration among meniscectomy guinea pigs, which exhibited superior performance to celecoxib in both cartilage metabolism and maintenance of SCB micro-architecture [27]. Antunes et al. argued that SCB contributed to the disruption of the cartilage, but PTH (1–34) protected the destruction of the SCB [37]. Zhang et al. supposed that PTH (1–34) improved cartilage metabolism and SCB health on patellar ligament shortening SD rats [42].
Different routines would differ the effect of PTH (1–34). Eswaramoorthy et al. found that controlled-release property of PTH (1–34) via intra-articular (IA) injection suppressed early stages of OA in papain-induced OA (PIOA) rats [22]. Chen et al. suggested that PTH (1–34) improved spontaneous OA by directly affecting the cartilage rather than the SCB or metaphyseal bone [43], reduce chondrocyte terminal differentiation and apoptosis, and increase autophagy on ACLT rats via IA injection [44]. Longo et al. concluded that PTH (1–34) promoted the regenerative and chondroprotective effects of the tissue-engineered meniscus by inhibiting the differentiation of mesenchymal stem cells (BMSC) chondrogenesis and cartilage degeneration among the meniscectomy dogs [30], which represented a promising method to increase the chance of regeneration in the tissue-engineered meniscus.
In vitro studies showed potential mechanism of PTH (1–34) intracellularly
Based on the inclusion criteria, 11 in vitro investigations were included in the SR (Table 2). These studies were conducted in numerous countries including China (Chang et al. 2009 [25], Shao et al. 2022 [45]; Chang et al. 2016 [46]), Canada (Mwale et al. 2010 [47]), USA (Funk et al. 1998 [48]), Sweden (Petersson et al. 2006 [49]), Australia (Music et al. 2020 [50]), Japan (Tsukazaki et al. 1996 [51]; Dogaki et al. 2016 [52]; Hosokawa et al. 2015 [53]), and Netherlands (Rutgers et al. 2019 [54]).
Table 2
Characteristics of in vitro studies about the effect of teriparatide on OA
PTH (1–34) alleviates OA by increasing the migration, proliferation, and chondral matrix formation of OA chondrocytes by inhibiting proinflammatory cytokines
p38 and AKT protein kinase signaling pathways may not be required to initiate the regulation of expression of COLII and COLX by PTH (1–34), which is necessary for preventing precocious MSC hypertrophy
Proinflammatory cytokine-stimulated production of NH2 terminal PTHrP by synovial tissue directly invading cartilage and bone in RA, which might mediate joint destruction through direct effects on cartilage or indirectly via the induction of mediators of bone resorption
PTH (1–34) regulates ATDC5 cells in both chondrogenesis and the circadian clock as time-dependent properties of chondrocyte function and differentiation
PTH (1–34) inhibits healthy human articular chondrocytes regeneration other than hypertrophic differentiation
PTH (1–34) may be suitable for cartilage repair based on MSCs
OA Osteoarthritis, BMSCs Bone marrow mesenchymal stem cells, PTH (1–34) Teriparatide, nM nmol/L, PTHrP Parathyroid hormone-related protein, M mol/L, MSC Mesenchymal stem cells, COL II Type II collagen, COLX Type X collagen, RA Rheumatoid arthritis, pM pmol/L, μM μmol/L
As for the effects on human articular chondrocytes, PTH (1–34) influenced its differentiation and regeneration. Tsukazaki et al. concluded that PTHrP was an important autocrine and paracrine factor for chondrocyte metabolism as for cell growth and differentiation [51]. Rutgers et al. suggested that PTH (l–34) inhibited healthy human articular chondrocyte regeneration but did not influence hypertrophic differentiation [54]. Chang et al. concluded that PTH (l–34) could reverse the terminal differentiation of chondrocytes without affecting normal chondrocytes, while PTHrP prevented the chondrocyte degeneration initiated by dexamethasone [25]. Moreover, Chang et al. held that PTH (1–34) treated early OA without affecting normal chondrocytes [55]. When PTH (1–34) was applied for RA or OA chondrocytes treatment, the survival and inflammatory cytokines would be affected. Petersson et al. found that PTH (1–34) increased the proliferation of chondrocytes from human and RA patients [49]. However, Funk et al. revealed that the PTHrP could be examined in synovium and synoviocytes obtained from RA patients, which help to clarify the pathogenesis of RA to a certain extent and remain to be investigated further [48]. In addition, Lugo et al. found that PTH (1–34) ameliorated OA by improving SCB integrity, inhibiting cartilage degradation, and exerting effects on synovial changes [38]. PTH (1–34) held potential therapeutic option for synoviopathy associated with OA.
PTH (1–34) protected MSC with various effects. Shao et al. maintained that PTH (1–34) worked on MSC by increasing the migration, proliferation, ECM formation, and inhibiting proinflammatory cytokines [56]. Mwale et al. argued that PTH (1–34) helped to prevent precocious MSC hypertrophy [47]. Music et al. believed that PTH (1–34) suppressed MSC hypertrophic [50]. Dogaki et al. implied that PTH (1–34) may not have a positive effect at the fracture site because no positive effect was noticed when the fracture haematoma-derived progenitor cells were treated with PTH (1–34) [52]. Hosokawa et al. indicated that PTH (1–34) could reset the circadian rhythm of ATDC5 cells, which is expected to be useful to assess the molecular mechanisms of PTH (1–34) on chondrogenic differentiation [53]. PTH (1–34) played a significant role in chondrocytes through affecting the proliferation and ECM synthesis.
Anzeige
Quality assessment of included studies
Methodological quality was assessed for all 33 involved studies (Fig. 3). An unclear risk of selection bias (because of lacking data regarding randomization method: n = 16); detection bias (blinding of outcome assessment, n = 20); performance bias (because of absent data about blinding of subjects, n = 11), attrition bias (n = 17), reporting bias (n = 21), and other bias (n = 15) were found.
Fig. 3
Risk of bias assessment across the studies (n = 33). Methodological quality was assessed for all involved studies
×
Discussion
To our knowledge, this is the first SR evaluating the existing papers about the effect of PTH (1–34) on OA regarding in vivo and in vitro investigations. The chondro-protective and cartilage-regenerative effects were reviewed, indicating that PTH (1–34) might be a potential preventative and therapeutic treatment for OA.
OA is the most prevalent degenerative joint disease with complicated pathogenesis characterized with damage to cartilage, narrow synovial cavity, invasion of the SCB, formation of osteophytes, and synovitis [57]. OP is a metabolic bone disease with decreased bone strength but increased fracture risk. OP and OA are common clinical conditions with high prevalence among older adults. Antiresorptive agents exhibited effects on bone mineralization and cartilage degradation for OA or OPOA [58]. However, treatments with polypharmacy for OA are limited to pain relief with less effective, which should be individualized to reduce the risk of side effects [59]. And therefore, DMOADs are highly demanded for OA or OPOA.
Quantitative studies indicated that PTH (1–34) played a significant role in calcium metabolism with an anabolic effect in the treatment of OP, fracture healing, non-union and stress fracture, augmentation of implant fixation, and chondro-protection in OA [14, 60]. In addition, PTH (1–34) could be a systemic pharmacology for OA by influencing cartilage quality such as ECM and chondrocyte contents [61]. The effects of PTH (1–34) were involved in decreasing COLX or RUNX2 but increasing AGC [34], which not only inhibited matrix metallopeptidase 13 (MMP13) or ADAM metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS4), but also enhanced COLII and AGC [26, 42]. Moreover, PTH (1–34) reversed terminal differentiation towards hypertrophy and decreased apoptosis of chondrocytes [46, 47].
Anzeige
The anabolic effects of PTH (1–34) on both cartilage and SCB were explained by multiple mechanisms (Fig. 4). The activation of NF-κB elevated inflammatory mediators of IL-1β, TNF-α, cyclooxygenase-2 (COX2), and inducible nitric oxide synthase (iNOS), which resulted in the initiation of OA and regulated the levels of MMP13 [62]. It is well established that the parathyroid 1 receptor (PTH1R) was a key regulator to induce differentiation and endochondral ossification by inducing ECM synthesis, suppressing maturation, and inhibiting degeneration [20]. PTH (1–34) elevated the expression of PTH1R, osteoprotegerin (OPG), and receptor activator of NF-κB ligand (RANKL) via the OPG/RANKL/RANK signaling pathway [26]. The Notch pathway was activated by PTH (1–34) with increased expression of JAGGED1 [63]. The expression of TNF-α was inhabited by PTH (1–34) via the PKA signaling pathway [29]. PTH (1–34) inhibited chondrocyte differentiation towards hypertrophy via the p38 and the p-AKT signaling pathway [47]. PTH (1–34) downregulated JAK2/STAT3 and Wnt5A/ROR2 [19] but upregulated the Wnt/β-catenin through an alternative signaling pathway [64].
Fig. 4
Relevant mechanisms of PTH (1–34) in the chondrocytes. The chondrocyte-protective and chondrocyte-regenerative effect of PTH (1–34) were explained by multiple mechanisms
×
In addition, the attenuation of signaling pathways including oxidative stress and apoptosis had an indispensable role in OA. Autophagy was a protective mechanism in normal cartilage. PTH (1–34) alleviated OA progression by reducing terminal differentiation, reducing apoptosis, and increasing autophagy via the mechanistic target of rapamycin (mTOR) and p62 [21]. Apoptosis was reversed, while both Bcl-2 and Bax were upregulated by PTH (1–34). Moreover, PTH (1–34) might reduce the accumulation of senescent cells by inhibiting p16 [28]. Both the sustained and intermittent action of PTH (1–34) suppressed OA effectively [22, 65]. IA application would directly affect the cartilage rather than the SCB or metaphyseal bone [43]. PTH (1–34) inhibited the terminal differentiation of human chondrocytes in vitro and inhibits OA progression in rats in vivo [25]. PTHrP was up-regulated and mediated by calcium-sensing receptor in OA cartilage, which might promote both proliferation of chondrocyte and osteophyte formation [66]. Stimulation of focal osteochondral defect, enhancement of allograft bone union, and differentiation of MSCs are various effects of PTH (1–34) in tissue engineering [32, 67].
An ideal DMOAD can not only repair and regenerate cartilage, but also alleviate inflammation of synovium and pain. Healthy synovial joints are capable of maintaining extraordinary lubrication, attributed to structures as well as the cellular constitutions. However, both synovitis and OP contributed to cartilage degradation [68] but all pathology above could be suppressed by PTH (1–34) [69]. Impairment of SCB aggravated cartilage damage in early OPOA rabbits [39] and is associated with weight-bearing pain [70]. Overall, PTH (1–34) exhibited protective effects on the change of synovitis as well as pain relief.
Clinically, resorption played a significant role while PTH (1–34) was a reasonable option for OP patients [71]. Successful osteoanabolic treatment with PTH (1–34) benefited symptomatic stress concentration with completely stem tip pain-free [72]. The periprosthetic BMD was preserved after total hip arthroplasty (THA) [73] while bone ingrowth was promoted after total knee arthroplasty (TKA) [74] enforced by PTH (1–34). In addition, nonunion of periprosthetic fracture after TKA benefited from PTH (1–34) as well [75]. However, early mineralization of the MCC caused by PTH (1–34) might shift modifications of the subarticular spongiosa. Overall, we had better use the PTH (1–34) in proper situations and dosages.
Anzeige
There are some limitations in our current review. Firstly, the present review cannot identify the mechanisms accounting for the precious mechanism of PTH (1–34) on OA. Further research evidence is needed to deepen our current review. Secondly, although a thorough search was performed from five English databases, some pertinent studies may still have been missed. Thirdly, limited information in the current reviewed investigations is an urgent call for subsequent studies to confirm the findings based on additional information. Finally, there are only included studies published in English; thereby, some studies in other languages would be missed out.
Conclusion
In conclusion, the SR, which included both in vivo and in vitro studies, described the beneficial effects of PTH (1–34) on OA via alleviating cartilage damage progression, inhibiting the abnormal SCB remodeling, suppressing synovitis, reducing oxidative stress or apoptosis of chondrocytes, and elevating autophagy. Some of the OA or OAOP patients might benefit from PTH (1–34) as well. The present SR is a description of existing studies regarding the effectiveness of PTH (1–34) administration in OA together with mechanisms, which suggested the necessity for further clinical trials and animal investigations to achieve concise conclusions about the effects of PTH (1–34) on OA.
Acknowledgements
All persons who have made substantial contributions to the work reported in the manuscript but do not meet the criteria for authorship are named in the Acknowledgements. We especially thank professor Yingqi Chen, Anjaneyulu Udduttula, Xiaoyan Huang, Jianchen, and Canhui Cao, who offered their kind assistance in writing, editing, reviewing, technical help, and general support in methodology.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.
Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.
Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.
Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
